Equities

Covalon Technologies Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CVALF:QXE

Covalon Technologies Ltd

Actions
  • Price (USD)1.20
  • Today's Change-0.03 / -2.44%
  • Shares traded1.20k
  • 1 Year change-43.79%
  • Beta-0.2211
Data delayed at least 15 minutes, as of Feb 13 2026 20:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Covalon Technologies Ltd. is a Canada-based patient-driven medical device company that provides healthcare solutions for advanced wound care, infection control, and medical device coatings. The Company's solutions are designed for patients and made for care providers. The Company leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon's name, and by developing and commercializing medical products for other medical companies under development and license contracts. The Company has three proprietary platform technologies that have the potential to be developed into a number of medical devices and products: Collagen matrix, Antimicrobial silicone adhesive and Medical coatings. Its product type includes advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, and perioperative dressings. Its brands include ColActive PLUS, CovaClear, CovaView, CovaWound, IV Clear, SurgiClear, and VALGuard.

  • Revenue in CAD (TTM)32.82m
  • Net income in CAD2.06m
  • Incorporated2004
  • Employees--
  • Location
    Covalon Technologies Ltd1660 Tech Avenue, Unit 5MISSISSAUGA L4W 5S7CanadaCAN
  • Phone+1 (905) 568-8400
  • Fax+1 (905) 568-5200
  • Websitehttps://covalon.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.